A Population-Based Nested Case-Control Study in Taiwan: Use of 5α-Reductase Inhibitors Did Not Decrease Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia

BACKGROUND. 5α-Reductase inhibitors (5ARIs) are commonly used to treat benign prostate hyperplasia (BPH) by blocking the conversion of testosterone into the more potent dihydrotestosterone. This study explored a possible association between the use of the 5ARIs finasteride and dutasteride and the su...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Liang, Ji-An, Sun, Li-Min, Lin, Ming-Chia, Chang, Shih-Ni, Sung, Fung-Chang, Muo, Chih-Hsin, Kao, Chia-Hung
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2012
Assuntos:
Outcomes Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399656/
https://ncbi.nlm.nih.gov/pubmed/22723508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0464
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares